The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Open accessAbstract
Key Points: Ibrutinib induced a high rate of sustained responses for patients with cGVHD and inadequate response to corticosteroid-containing therapy. This trial supported the approval of ibrutinib for treatment of adult patients with cGVHD after failure of ≥1 lines of systemic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citation
Cited by
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Immunopathology of Hyperinflammation in COVID-19
Gustine, J. N., & Jones, D. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.009 · Cited by 516
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy175 · Cited by 271
ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease
Jagasia, M., Lazaryan, A., Bachier, C. R., Salhotra, A., Weisdorf, D. J., Zoghi, B., Essell, J., Green, L., Schueller, O., Patel, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02754 · Cited by 198
Self-citation
Metadata
- Authors
- Miklos, D., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Blazar, B. R., Li, Y., Chang, S., Lal, I., Dubovsky, J., James, D. F., Styles, L., & Jaglowski, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-11-23
- Volume
- 130
- Issue
- 21
- Pages
- 2243-2250
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2754850852
- Cited by
- 514
- References
- 1
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. https://app.cochat.ai/papers/10.1182/blood-2017-07-793786
- The paper
- Miklos, D., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Blazar, B. R., Li, Y., Chang, S., Lal, I., Dubovsky, J., James, D. F., Styles, L., & Jaglowski, S. (2017). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. https://doi.org/10.1182/blood-2017-07-793786
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
